BioStock: PHI’s CEO comments on the approved US listing
Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.
Read the full interview with Patrik Eschricht on biostock.se.
Further reading
BioStock: The five best life science stocks of the first half-year
BioStock: PHI’s CEO reflects on global roadshow success
BioStock: PHI on how TO 3 proceeds will be used